Loading…
DMAC
DiaMedica Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 25253X207
$7.78+7.16%Price as of Sep 22, 22:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $419.54M
- P/E
- —
- Forward P/E
- —
- P/B
- 10.9x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.72
- ROE
- -114.61%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.97
- 52-week high
- $10.42
- 52-week low
- $5.25
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +101.0% over 5Y.
today you would have $1,980.05▲ +98.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $7.96 | $5.43 | $2.84 | $1.58 | $3.73 | $10.14 | $4.85 | $2.91 | $5.00 | |
| P/S | — | — | — | — | — | — | — | — | 69.6x | — |
| P/B | 5.7x | 7.6x | 5.7x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CGCCanopy Growth Corp | $0.94 | — | 0.8x | — | -39.51% | $420.27M |
| CABACabaletta Bio, Inc. | $2.50 | — | 2.0x | — | -93.20% | $423.86M |
| CYHCommunity Health Systems Inc | $3.01 | 1.6x | — | — | — | $424.44M |
| EDITEditas Medicine, Inc. | $2.69 |
About the company
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
- 35
- Minneapolis, United States
Company description provided by Yahoo Finance.